Sign In
Buy RHHBY
$51.57
+2.51 (+5.12%)
At Close: Jun 04, 2026
Roche Increases Dividend on Higher Sales
01:30am, Wednesday, 23'rd Oct 2024
Roche said it would increase its dividend after its hemophilia injection Hemlibra and multiple sclerosis treatment Ocrevus lifted sales in the first nine months of the year.
Roche Q3 sales advance by forex-adj 9%, beating market view
01:18am, Wednesday, 23'rd Oct 2024
Roche on Wednesday said that third-quarter sales gained a currency-adjusted 9% to 15.14 billion Swiss francs ($17.46 billion).
Roche CEO Thomas Schinecker: “Our strong growth momentum continued in the third quarter, reflecting the high demand for our innovative medicines and diagnostic solutions and their positive impact on
Can Roche Challenge Lilly and Novo in the Weight Loss Market?
10:54am, Tuesday, 22'nd Oct 2024
Over the last couple of years, one of the biggest stories in the stock market has been around pharmaceutical companies that are thriving due to the proliferation of their weight loss drug treatments.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline one-year results from the open-label, single-arm Pha
Roche's Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study
05:00pm, Friday, 18'th Oct 2024
Basel, 18 October 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline one-year results from the open-label, single-arm phase IV ELEVATUM study evaluating Vabysmo® (faricimab) f
Astellas' VYLOY™ (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer
02:13pm, Friday, 18'th Oct 2024
VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive TOKYO , Oct. 18, 2
The new VENTANA CLDN18 (43-14A) RxDx Assay helps fulfil an unmet medical need by enabling clinicians to identify patients with gastric or gastroesophageal junction (GEJ) cancer who may benefit from a
China is 'fighting hard', but mainly in the wrong direction: David Roche
11:22pm, Thursday, 17'th Oct 2024
David Roche of Quantum Strategy says the complexity of the issue in China is not being comprehended by the authorities, and discusses what measures he thinks are needed to "get the economy moving".
Roche Wins FDA Nod for Breast Cancer Drug in First-Line Setting
02:40pm, Monday, 14'th Oct 2024
RHHBY obtains FDA approval for Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented positive 2-year data from the ongoing RAINBOWFISH study at the 29th World M
Basel, 14 October 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented positive two-year data from the ongoing RAINBOWFISH study at the 29th World Muscle Society (WMS) Congress, 8-12 October, 2024, ass
Basel, 11 October 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the United States Food and Drug Administration (FDA) approved Itovebi™ (inavolisib), in combination with palbociclib
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved Itovebi™
The company is preparing for the Phase 3 study start in the first quarter of 2025 The company is preparing for the Phase 3 study start in the first quarter of 2025
